Sun Pharma.Inds.
Sun Pharma.Inds. Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and fundraising.
The short version
Organon's current growth is modest, around 1-2% annually in established products. Sun Pharma expects long-term value creation from the Organon acquisition, focusing on growth beyond short-term (6-12 months) horizons.
From Sun Pharma.Inds.'s Q4 FY26 earnings-call transcript · updated 23 Sept 2026.
Revenue & Sales Performance
- Organon's current growth is modest, around 1-2% annually in established products.
- Sun Pharma aims to boost growth by applying its branded generic playbook and better execution.
- Growth drivers include leveraging Organon's global commercial footprint, entering 10 new markets, and using its own field force.
- In-licensing of products close to market and pipeline assets is a key strategy to enhance growth, especially in women's health.
- Biosimilars and innovative products like VTAMA and ILUMYA will contribute to future revenue growth.
2 more points from Sun Pharma.Inds.'s call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Sun Pharma.Inds. said on profitability & margins — free account, 30 seconds.
Fundraising & Capital Structure
- Sun Pharma will be taking on a significant amount of debt to close the Organon acquisition.
- The combined company's debt to EBITDA ratio post-transaction is around 2.3x, considered manageable by current standards.
- Management intends to focus on repaying this debt as early as possible.
- There is no commentary on new equity fundraising; the acquisition is a cash deal.
- The company aims to maintain dividend payments but has yet to finalize this stance.
2 more points from Sun Pharma.Inds.'s call on fundraising
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Sun Pharma.Inds. — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹14.6K Cr, net profit ₹2.7K Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Sun Pharma.Inds.'s management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharmaceuticals Ltd (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pharmaceuticals Ltd (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn Ltd (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Arthneeti Pro · Annual
Sun Pharma.Inds. and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Sun Pharma.Inds. Q4 FY26 results?
Organon's current growth is modest, around 1-2% annually in established products. Sun Pharma expects long-term value creation from the Organon acquisition, focusing on growth beyond short-term (6-12 months) horizons.
What is Sun Pharma.Inds. share price analysis?
Sun Pharma.Inds. currently shows a neutral. The stock trades at a P/E of 34.9 with a market cap of ₹440,830 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sun Pharma.Inds. planning capital expenditure?
Organon's long-term financial plans, including capex or capital investments, have been factored into the valuation but specifics are not disclosed at this time.
Keep Sun Pharma.Inds. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.